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Abstract
Background: Normal thyroid hormone secretion or appropriate L-thyroxine (L-T4) substitution is necessary for the
optimal effect of the growth hormone (GH) administration on growth rate. The decrease of free thyroxine (FT4)
levels at recombinant human GH (rhGH) therapy onset has been reported in several studies. The aim of the
present study was to evaluate the effect of rhGH administration on thyrotropin (TSH) and FT4 serum concentrations
in children with GH deficiency (GHD) during the 1st year of therapy, as well as to assess potential indications to
thyroid hormone supplementation in them.
Patients and methods: The analysis involved data of 75 children (59 boys, 16 girls) with disorders of GH secretion
(GHD, neurosecretory dysfunction - NSD) and partial GH inactivity (inactGH), who were treated with rhGH for - at
least - one year. In all the children, body height and height velocity (HV) were assessed before and after 1 year of
therapy, while TSH, FT4, IGF-I and IGFBP-3 before treatment and after 3-6 months and 1 year of treatment. In the
patients, who revealed hypothyroidism (HypoT), an appropriate L-T4 substitution was introduced immediately. The
incidence of HypoT, occurring during the initial phase of rhGH therapy, was assessed, as well as its influence on
the therapy effectiveness.
Results: Before rhGH substitution, there were no significant differences in either auxological indices or TSH and FT4
secretion, or IGF-I concentration and its bioavailability among the groups of patients. During the initial 3-6 months
of rhGH administration, a significant decrease of FT4 serum concentration, together with a significant increase of
IGF-I SDS and IGF-I/IGFBP-3 molar ratio was observed in all the studied groups. In 17 children, HypoT was
diagnosed and L-T4 substitution was administered. Despite similar IGF-I secretion increase, the improvement of HV
presented significantly lower in children with HypoT than in those who remained euthyroid all the time.
Conclusions: The incidence of HypoT during the initial phase of GH treatment in children with GHD and the
negative effect of even transient thyroid hormone deficiency on the growth rate should be taken into account.
Background
Growth hormone (GH) deficiency (GHD) in children
with short stature is an unchallenged indication to the
therapy with recombinant human GH (rhGH). The
main goal of the treatment is to increase patients’ height
velocity (HV) and to improve the attained final height
(FH). The most important peripheral mediator of GH
activity is the insulin-like growth factor-I (IGF-I). The
insulin-like growth factor binding protein-3 (IGFBP-3) is
the main carrier protein binding to IGF-I in plasma,
thus determining its bioavailability. Besides, either nor-
mal thyroid hormone secretion or appropriate substitu-
tion of L-thyroxine (L-T4) is necessary for the optimal
effect of both endogenous GH and rhGH substitution
on the growth rate.
The relationships between GH secretion and thyroid
function, as well as the effects of rhGH administration on
thyroid hormone levels have been the subject of numer-
ous studies. The data of Cacciari et al. [1], presented 30
years ago, indicated that the risk of inducing an alteration
in thyroid function in hypopituitary patients during
rhGH therapy was only slight and that the abnormal
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returned to normal limits during follow-up. Next, Gács
and Bános [2] reported that rhGH therapy in children
with idiopathic GHD reduced T4 secretion and affected
the peripheral metabolism of thyroid hormones, resulting
in an increase of T3. In 1994, Jørgensen et al. [3] reported
that, in GH-deficient adults, rhGH administration stimu-
lated peripheral T4 to T3 conversion in a dose-dependent
manner and influenced circadian rhythm of thyrotropin
(TSH) secretion. Moreover, in some of those patients
before rhGH administration, serum T3 levels were sub-
normal despite T4 substitution and normalised during
the therapy. As it was shown that rhGH administration
m i g h ti n d u c eaf a l li ns e r u mT 4, it seemed probable that
GHD could mask secondary hypothyroidism in some
patients with hypopituitarism. Recently, Agha et al. [4]
proved that rhGH administration really led to „unmask-
ing” hypotyroidism in hypopituitary adults. Similar were
the observations of Losa et al. [5], who reported that, in
adults with GHD, administration of rhGH therapy was
associated with a significant decrease of free T4 (FT4)i n
first 6 months of treatment.
First reports, concerning the effects of rhGH therapy
on thyroid hormone levels in children also confirmed an
increase of extrathyroidal conversion of T4 to T3 during
the therapy [6]. Conversely than described for adults [5],
as early as in 1994, Laurberg et al. [7] stated that chil-
dren with GHD, evaluated thoroughly to exclude sec-
ondary thyroid failure before rhGH administration, did
not develop hypothyroidism during rhGH substitution.
Up to now, several interesting studies have been pub-
lished on long-term effects of rhGH replacement ther-
apy on thyroid function, both in adults [8-10] and in
children [11-18].
The aim of current study was to evaluate the effect of
rhGH substitution on TSH and FT4 serum concentra-
tions in children with GHD during the 1
st year of ther-
apy, as well as to assess potential indications to thyroid
hormone supplementation in them.
Patients and methods
The retrospective analysis involved the data of 75 chil-
dren (59 boys, 16 girls) with GHD, who were qualified to
rhGH therapy. At therapy onset, the patients’ height was
below the 3rd centile, according to Polish reference
charts [19], HV was slow (below -1.0 SD/year), bone age
was delayed, according to Greulich-Pyle’s standards [20].
Thyroid function was normal in most of children
(67 cases). In the remaining 8 patients, L-T4 supplemen-
tation had been administered, due to either hyperthyro-
tropinemia or relatively low (normal but close to the
lower limit of reference range) FT4 concentration and
pharmacological euthyrodism was then confirmed. In all
the children IGF-I and IGFBP-3 secretion was measured
in a single blood sample during in morning hours. In
most of the children, IGF-I concentration was either
decreased or close to lower limit of normal range. It
should be mentioned that - though IGF-I is the main per-
ipheral mediator of GH action - children with normal
IGF-I secretion may be diagnosed as GH-deficient and
qualified to rhGH therapy in the light of current national
recommendations, enclosed in the programme of therapy
of GHD in children with rhGH [21]. In all the patients,
nocturnal GH secretion was assessed during 3 hours
after falling asleep (5 samples every 30 minutes from the
60th to the 180th minute) and 2 stimulating tests were
performed (with clonidine 0.15 mg/m
2 orally and with
glucagon 30 μg/kg, not exceeding 1 mg, i.m.). The diag-
nosis of GHD was established when GH peak during
nocturnal assessment and in both stimulating tests was
below 10 ng/ml. Neurosecretory dysfunction (NSD) was
diagnosed in children with normal results of stimulating
tests but decreased nocturnal GH secretion (that obser-
vation had to be confirmed by documenting decreased
GH secretion in prolonged, 6-hour nocturnal profile). In
children with decreased IGF-I secretion and normal GH
peak (both in nocturnal profile and after pharmacological
stimulation), IGF-I generation test was performed after
exclusion of other causes of IGF-I deficiency, not related
to GH secretion disorders and GH action (like malab-
sorption syndromes, liver diseases, malnutrition, other
severe chronic diseases). Interestingly enough, a good
response to rhGH administration - at least, twofold
increase of IGF-I secretion, leading to normalisation of
its level in plasma - was observed in each case, thus
allowing exclusion of GH insensitivity and pointing at
decreased bioactivity of endogenous GH in these chil-
dren. The obtained results of that test supported the indi-
cations to rhGH administration in them. Children with
either other hormonal deficiencies or severe and/or
chronic, growth influencing diseases, as well as those
with acquired GHD, were not included to the studied
group. All the girls had normal female karyotype.
At rhGH therapy onset, patients’ age was 12.2 ± 2.4
years (mean ± SD). The therapy with rhGH in a dose of
0.21 ± 0.02 mg (0.63 ± 0.05 IU)/kg/week was adminis-
tered for, at least, 1 year. In every patient, TSH and FT4
concentration was assessed three times: before the first
rhGH injection, after 3-6 months and at after 1 year of
treatment; all the blood samples were taken in morning
hours. Additionally, IGF-I and IGFP-3 concentrations
were measured at the same time points and IGF-I stan-
dard deviation score (SDS) for age and sex, as well as
IGF-I/IGFBP-3 molar ratio was calculated.
Plasma TSH and FT4 concentrations were measured by
the electroimmunochemiluminescent method (ECLIA),
Roche, Elecsys®Systems 1010/2010/modular analytics
E170. For TSH, analytical sensitivity was 0.005 μIU/ml,
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iance (CV) - 1.5-8.6%, accuracy - 1.1-3.0%. Analytical
range for FT4 was 0.023-7.77 ng/dl, intra-assay CV - 1.4-
2.9%, accuracy - 2.7-6.6%.
Growth hormone concentrations were measured by
hGH Immulite, DPC assay, calibrated to WHO IRP 80/
505 standard, with analytical sensitivity up to 0.01 ng/ml,
calibration range up to 40 ng/ml, sensitivity of 0.01 ng/ml,
intra-assay CV - 5.3-6.5% and inter-assay CV - 5.5-6.2%.
Both IGF-I and IGFBP-3 concentration was assessed by
Immulite, DPC assays. For IGF-I, WHO NIBSC 1
st IRR
87/518 standard was applied, with analytical sensitivity
20 ng/ml, calibration range up to 1600 ng/ml, intra-assay
CV - 3.1-4.3% and inter-assay CV - 5.8-8.4%. For com-
parison among children of different age and sex, IGF-I
concentrations were expressed as IGF-I SDS, according
to DPC reference data. The assay for IGFBP-3 assessment
was calibrated to WHO NIBSC Reagent 93/560 standard,
with analytical sensitivity 0.02 μg/ml, the calibration
range up to 426 μg/ml, the intra-assay CV - 3.5-5.6% and
the total CV - 7.5-9.9%. For calculation of IGF-I/IGFBP-3
molar ratio, the following molecular masses were used:
7.5 kDa for IGF-I and 42.0 kDa for IGFBP-3 [22]. For
comparison among children with different age and sex,
IGF-I concentrations were expressed as SD score (IGF-I
SDS), according to DPC reference data.
Statistical analysis included comparison of thyroid func-
tion (FT4 and TSH concentrations), IGF-I secretion
(as IGF-I SDS) and its bioavailability (expressed as IGF-I/
IGFBP-3 molar ratio) in particular time points, before and
during rhGH therapy. Non-parametric Wilcoxon’s test for
dependent samples was applied, as the distribution of the
analysed parameters (assessed with Kolmogorov-Smirnov’s
test) presented not consistent with normal distribution.
The differences among particular subgroups of patients in
the same time point were assessed with non-parametric
Kruskall-Wallis’ test for independent samples. The level of
statistical significance was at p < 0.05.
Results
Before rhGH substitution, there were no significant dif-
ferences in either auxological indices or TSH and FT4
secretion, or IGF-I concentration and its bioavailability
among the groups of patients with GHD, NSD and
inactGH. Moreover, all the differences among the
groups at particular time points (i.e.b o t ha f t e r3 - 6
months and after 1 year of rhGH therapy) still remained
insignificant, except for significantly lower TSH in
inactGH than in both GHD and NSD after 1 year of
rhGH treatment (see Table 1). Interestingly enough, the
changes in FT4 and TSH concentration were similar in
children with previously normal thyroid function
(67 cases) and in those on L-T4 substitution at rhGH
therapy onset (8 cases). Detailed comparisons of the
Table 2 Selected auxological and hormonal data in
euthyroid vs. previously L-T4 treated patients
euthyroid L-T4 treated p
n6 78
Before rhGH administration
age [years] 12.3 ± 2.2 10.8 ± 3.6 0.15
height SDS -2.65 ± 0.54 -3.13 ± 0,76 0.07
HV [cm/year] 3.6 ± 0.9 3.8 ± 1.0 0.71
TSH [mU/l] 2.42 ± 0.91 2.18 ± 1.02 0.27
FT4 [ng/dl] 1.26 ± 0.15 1.30 ± 0.15 0.97
IGF-I SDS -2.00 ± 0.98 -2.23 ± 1.72 0.87
IGF-I/IGFBP-3 0.18 ± 0.06 0.19 ± 0.11 0.97
After 3-6 months of rhGH therapy
TSH [mU/l] 2.68 ± 1.38 2.75 ± 0.74 0.52
FT4 [ng/dl] 1.12 ± 0.13 1.17 ± 0.37 0.16
IGF-I SDS 0.49 ± 0.83 0.16 ± 1,30 0.29
IGF-I/IGFBP-3 0.39 ± 0.11 0.31 ± 0.13 0.21
After 1 year of rhGH therapy
HV [cm/year] 9.8 ± 2.1 11.7 ± 1.1 0.01
TSH [mU/l] 2.14 ± 0.90 2.94 ± 1.98 0.27
FT4 [ng/dl] 1.29 ± 0.16 1.21 ± 0.22 0.55
IGF-I SDS 0.67 ± 0.77 0.61 ± 1.31 0.72
IGF-I/IGFBP-3 0.42 ± 0.11 0.37 ± 0.15 0.64
Table 1 Selected auxological and hormonal data of the
patients with respect to the initial diagnosis
Diagnosis p
GHD NSD inactGH
n 3 62 31 6
Before rhGH administration
age [years] 12.0 ± 2.4 12.0 ± 2.9 12.9 ± 1.4 0.56
height SDS -2.59 ± 0.53 -2.91 ± 0.68 -2.68 ± 0.49 0.57
TSH [mU/l] 2.42 ± 0.91 2.18 ± 1.02 2,63 ± 0.94 0.69
FT4 [ng/dl] 1.31 ± 0.13 1.28 ± 0.17 1.29 ± 0.15 0.45
IGF-I SDS -1.77 ± 0.92 -2.18 ± 1.23 -2.36 ± 1.06 0.58
IGF-I/IGFBP-3 0.21 ± 0.08 0.16 ± 0.05 0.16 ± 0.05 0.31
After 3-6 months of rhGH therapy
TSH [mU/l] 2.80 ± 1.28 2.60 ± 1.20 2.56 ± 1.60 0.77
FT4 [ng/dl] 1.13 ± 0.17 1.13 ± 0.19 1.13 ± 0.13 0.73
IGF-I SDS 0.33 ± 0.99 0.40 ± 0.89 0.33 ± 0.74 0.38
IGF-I/IGFBP-3 0.38 ± 0.13 0.37 ± 0.11 0.38 ± 0.11 0.86
After 1 year of rhGH therapy
TSH [mU/l] 2.51 ± 1.23 2.15 ± 0.74 1.56 ± 0.45 0.005
FT4 [ng/dl] 1.29 ± 0.18 1.27 ± 0.18 1.27 ± 0.13 0.72
IGF-I SDS 0.78 ± 0.88 0.62 ± 0.69 0.45 ± 0.83 0.72
IGF-I/IGFBP-3 0.43 ± 0.12 0.41 ± 0.11 0.39 ± 0.09 0.86
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Table 2. Among the patients who had L-T4 substitution,
administered before rhGH therapy onset, the decrease
of FT4 below the lower limit of normal range was
observed in 2 out of 8 cases and in those children, an
increased dose of L-T4 was necessary to restore euthyr-
oidism. A significant decrease of FT4 serum concentra-
tion was observed during the initial 3-6 months of
rhGH administration, together with insignificant
increase of TSH in all the studied groups, as well as in
particular subgroups of patients. For more detailed data
see Table 1 and Figure 1 and Figure 2.
Simultaneously, a significant increase of IGF-I SDS
was observed not only on the 3-6th month of rhGH
therapy, with respect to pre-treatment values, but also
after 1 year of therapy vs. the values obtained on the
3-6th month of treatment. Significant differences in
IGF-I SDS in particular time points were observed for
all the subgroups, expect for that between the values on
the 3-6th month and after 1 year in the subgroup with
inactGH. Similarly, a significant increase of IGF-I/
IGFBP-3 molar ratio was observed on the 3-6th month
of rhGH therapy, with respect to pre-treatment values,
h o w e v e r ,w i t ho n l yav e r ys l i g h tf u r t h e ri n c r e a s e( i n s i g -
nificant) after 1 year of therapy, both in all the studied
groups and in the subgroups of patients. The more
detailed data are presented in Figure 3 and Figure 4.
I n t e r e s t i n g l ye n o u g h ,t h e r ew e r en os i g n i f i c a n t
Figure 1 Free thyroxine serum concentrations before and during rhGH therapy in particular subgroups of patients with respect to the
initial diagnosis.
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Page 4 of 11Figure 2 Thyrotropin secretion before and during rhGH therapy in particular subgroups of patients with respect to the initial
diagnosis.
Figure 3 IGF-I secretion (expressed as IGF-I SDS for age and sex) before and during rhGH therapy in particular subgroups of patients
with respect to the initial diagnosis.
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ratio, observed among the particular subgroups of chil-
dren at any time point (see Table 1).
According to our observations, the therapy with rhGH
led to a similar increase of IGF-I secretion and of its
bioavailability in the patients with different forms of dis-
orders of GH secretion and activity. During the initial
phase of rhGH replacement therapy, a transient decrease
of FT4 concentration was observed in all the subgroups
of patients, in most subjects being connected with an
increase of TSH secretion. Spontaneous normalisation
of FT4 concentration on the level close to the values
obtained before rhGH administration, observed in the
majority of patients, presented parallel to further
increase of IGF-I secretion.
In 17 children, out of 67 previously untreated with L-
T4 (25.4%), either FT4 concentration decreased below
the lower limit of normal range (8 cases) or TSH
increased above the upper limit of the normal range (8
cases), or both (1 case). In those patients, L-T4 therapy
was administered just after the diagnosis of hypothyroid-
ism was established, in the initial daily dose of 25 μg,
individually adjusted under control of TSH and FT4
levels. In the remaining 50 patients, TSH and FT4 con-
centrations returned to pretreatment values at the end
of the 1st year of rhGH administration. Thus, in all the
children both TSH and FT4 concentrations after 1 year
of rhGH therapy were normal. It should be reminded
that all the children were euthyroid at rhGH therapy
onset.
In the patients, in whom hormonal evaluation after
3-6 months of rhGH administration led to the diagnosis
of HypoT (at least in subclinical form), TSH levels were
significantly higher, while FT4 concentrations - signifi-
c a n t l yl o w e rt h a ni nt h o s ec h i l d r e nw h or e m a i n e d
euthyroid during rhGH administration. There were no
significant differences between them in either IGF-I SDS
or IGF-I/IGFBP-3 molar ratio at that time point. More-
over, after 1 year of rhGH administration there were no
significant differences either in IGF-I secretion or in
IGF-I/IGFBP-3 molar ratio between the groups of chil-
dren who were euthyroid all the time and the other one,
grouping children who required L-T4 substitution. How-
e v e r ,i ts h o u l db ee m p h a s i z e dt h a tT S Ha n dF T 4 levels
in all of them were normal at the latter time point.
Nevertheless, some differences between the groups were
observed and should be mentioned. Surprisingly, IGF-I
SDS presented lower (however only insignificantly) in
those children who remained euthyroid during all the
study period, than in those, who presented with
hypothyroidism after 3-6 months of rhGH replacement.
Another important observation was a further increase of
Figure 4 IGF-I bioavailability (expressed as IGF-I/IGFBP-3 molar ratio) before and during rhGH therapy in particular subgroups of
patients with respect to the initial diagnosis.
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respect to the values obtained after 3-6 months. Never-
theless, after 1 year of rhGH therapy, HV improvement
(expressed both as the difference and as the ratio
between HV during and before the therapy) was signifi-
cantly lower in those children who were hypothyroid
even for a relatively short period of time during the
initial phase of rhGH therapy. It should be stressed that
L-T4 substitution was administered as soon as possible
when hypothyroidism was diagnosed. For detailed data
see Table 3 and Figure 5, Figure 6 and Figure 7.
Discussion
The phenomenon of T4 and FT4 concentration decrease
after rhGH administration in GH-deficient subjects has
been reported in several studies [1,2,5,9,12,14]. Also, the
return of thyroid function to baseline during follow-up
has been quite well documented [13,15,17,18]. Our
results confirm previous observations, concerning these
problems.
Moreover, it has been suggested that rhGH therapy
might disclose previously unrecognised thyroid insuffi-
ciency rather than induce hypothyroidism [4,7,14]. The
data, concerning the development of central
hypothyroidism in terms of rhGH substitution, seem to be
rather scarce and non-consistent. In 2007, Agha et al. [7]
stated that GHD masked central hypothyroidism in a sig-
nificant proportion of hypopituitary adults. Conversely, in
2008, Lose et al. [5] reported only a low incidence of
hypothyroidism in GH-deficient adults on rhGH substitu-
tion. Similar were the observations of Laurberg et al. [7]
and Giavoli et al. [16] in GH-deficient children, beginning
rhGH therapy. In our study, in 15% of previously euthyr-
oid children, a decrease of FT4 level with no adequate
increase of TSH was observed, (it should be stressed that
children with evident central hypothyroidism before rhGH
administration, being a component of multiple pituitary
hormone deficiency, were not included in current study).
Thus, our observations confirm the phenomenon of
„unmasking” central hypothyroidism after rhGH therapy
administration in some of children with previous diagnosis
of isolated GHD. Changes in TSH secretion during initial
period of rhGH substitution are less evident than fluctua-
tions of FT4 concentration. Most researchers reported
either a lack of significant changes in TSH secretion
[1,4,6,9,14,16,18] or a decrease of TSH level in terms of
rhGH administration [8,15,17]. The last phenomenon has
been explained by an increase of somatostatin (being a
natural TSH inhibitor) in the patients on rhGH therapy
[15]. In our study, the mean TSH serum concentration
presented a slight increase, followed by a recovery to pre-
treatment level. It seems that the differences among the
results obtained in different studies might be related to
different study protocols and analysed time points.
The most frequently quoted mechanism of changes in
thyroid hormone levels is GH-mediated increase of per-
ipheral T4 to T3 deiodination [7-9,12,14]. Moreover, a
potential role of IGF-I in stimulating that process has been
suggested by Jørgensen et al. [9]. The relationships
between GH, IGF-I and thyroid hormone secretion have
been subject of numerous studies. More than 25 years ago,
in 1983, Chernausek et al. [23] documented that plasma
somatomedin C (i.e. IGF-I) concentrations were dimin-
ished in hypothyroid patients, however, the pathogenesis
of this phenomenon remained unclear. Either diminished
GH secretion or direct effects of hypothyroidism upon
somatomedin production were considered. In early 1990s,
Näntö-Salonen et al. [24] stated that the mechanisms of
thyroid hormone action on the insulin-like growth factor
system were not GH-mediated. Similar were the observa-
tions of Inukai et al. [25], concerning the patients with
autoimmune thyroid diseases. In 2003, Iglesias et al. [26]
stated that hypothyroidism is associated with significant
reductions of IGF-1 and IGFBP-3. Next, Purandare et al.
[27] documented that in infants with hypothyroidism both
total and free IGF-I levels were lower than those in healthy
ones and increased significantly after L-T4 therapy, while
in older children with acquired hypothyroidism they were
Table 3 Selected auxological and hormonal data of the
patients according to thyroid function during rhGH
administration
euthyroid hypothyroid p
n5 0 1 7
Before rhGH administration
age [years] 12.4 ± 2.3 12.3 ± 2.1 0.94
height SDS -2.60 ± 0.50 -2.77 ± 0.63 0.38
HV [cm/year] 3.5 ± 1.0 3.8 ± 0.9 0.14
TSH [mU/l] 2.22 ± 0.95 2.65 ± 0.92 0.05
FT4 [ng/dl] 1.33 ± 0.15 1.21 ± 0.11 0.01
IGF-I SDS -2,01 ± 0.97 -1.99 ± 1.00 0.45
IGF-I/IGFBP-3 0.19 ± 0.07 0.18 ± 0.05 0.71
After 3-6 months of rhGH therapy
TSH [mU/l] 2.25 ± 0.92 3.71 ± 1.75 < 0.001
FT4 [ng/dl] 1.16 ± 0.10 1.01 ± 0.14 < 0.001
IGF-I SDS 0.37 ± 0.81 0.54 ± 0.81 0.59
IGF-I/IGFBP-3 0.38 ± 0.11 0.42 ± 0.12 0.36
After 1 year of rhGH therapy
TSH [mU/l] 2.07 ± 0.98 2.16 ± 0.79 0.54
FT4 [ng/dl] 1.31 ± 0.15 1.23 ± 0.14 0.11
IGF-I SDS 0.61 ± 0.67 0.83 ± 0.83 0.35
IGF-I/IGFBP-3 0.41 ± 0.09 0.45 ± 0.12 0.84
HV [cm/year] 10.0 ± 2.1 9.3 ± 2.0 0.23
ΔHV [cm/year] 6.5 ± 2.3 5.4 ± 2.1 0.01
ΔHV [%] 213 ± 118 154 ± 85 0.05
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trols. However, during L-T4 treatment an increase of total
IGF-I but not of free IGF-I was observed. Similarly, Bona
et al. [28] documented that in the patients with hypothyr-
oidism - both congenital and caused by thyroiditis - L-T4
replacement led to physiological increase of IGF-I and
IGFBP-3 secretion. Moreover, Schmid et al. [29] showed
that, during L-T4 replacement, IGF-I and acid-labile
subunit secretion increased in the patients with both pri-
mary and central hypothyroidism, while IGFBP-3 - only in
those with primary hypothyroidism. In 2008, Akin et al.
[30] reported that GH-IGF axis was affected in the
patients with subclinical hypothyroidism and that L-T4
replacement therapy could prevent abnormalities related
to GH-IGF axis in them. Moreover, at the same time, Soli-
man et al. [31] proved that, in children with neglected
Figure 5 IGF-I secretion (expressed as IGF-I SDS for age and sex) before and during rhGH therapy in the patients divided according to
the thyroid function during the initial phase of rhGH administration.
Figure 6 IGF-I bioavailability (expressed as IGF-I/IGFBP-3 molar ratio) before and during rhGH therapy in the patients divided
according to the thyroid function during the initial phase of rhGH administration.
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hypothyroidism, L-T4 replacement improved the growth
rate, leading to a partial recovery of GH-IGF-I axis.
In our study, differences were found between the
improvement of the growth rate in the patients with nor-
mal thyroid function and in those with even transient
hypothyroidism. As a matter of fact, a direct effect of thyr-
oid function on IGF-I secretion was not fully confirmed in
our study, as there were no significant differences in an
increase of IGF-I secretion between the euthyroid children
and those, who presented with hypothyroidism during
rhGH administration. However, further increase of IGF-I
secretion on the same rhGH dose was observed after 1
year of rhGH therapy, with respect to the values obtained
after 3-6 months of treatment. This phenomenon might
be explained either by the improvement of thyroid func-
tion (i.e. recovery to pre-rhGH-treatment values of FT4
and TSH) or by the appropriate L-T4 substitution.
Obligatory L-T4 supplementation from the beginning
of rhGH therapy in euthyroid patients has not been
recommended [17] due to a little evidence for the devel-
opment of clinically significant hypothyroidism in most
of previously euthyroid patients [13] and spontaneous
recovery to pre-treatment thyroid function in most
cases [13,15,17,18].
Our findings speak for the important role of maintain-
ing euthyroid status of the patients for the best effective-
ness of rhGH therapy, as even short-term, transient
hypothyroidism presented to be a cause of lower
increase of HV in 1st year of rhGH administration.
Thus, the incidence of revealing (or “unmasking”)
hypothyroidism should be taken into account, while
starting rhGH administration, as hypothyroidism may
worsen the response to the therapy. It seems that either
earlier assessment of TSH and FT4 concentration after
rhGH therapy onset or L-T4 administration from the
beginning of rhGH therapy in children with normal but
relatively low FT4 secretion and/or normal but relatively
high TSH levels should be taken into account. Further
studies seem necessary to fully assess the influence of
thyroid function (and thyroid hormone substitution) on
the effectiveness of rhGH therapy in children with disor-
ders of GH secretion. It seems also important to estab-
lish - if possible - the threshold values of pre-rhGH-
treatment TSH and/or FT4 levels predictive for revealing
hypothyroidism during rhGH administration.
Conclusions
The incidence of HypoT during the initial phase of
rhGH treatment in children with GHD and the negative
Figure 7 Height velocity increase in the 1
st year of rhGH therapy in the patients divided according to the thyroid function during the
initial phase of treatment.
Smyczynska et al. Thyroid Research 2010, 3:2
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growth rate should be taken into account while begin-
ning rhGH administration in them.
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